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LETTERS
Identity o f Interferon-ß 1 a Product in Multiple 
Sclerosis Study
Wieland W. Wolf, PhD
We extend .sincere congratulations to Dr Jacobs and col­
leagues for the successful conclusion o f  their study o f  recom­
binant interferon (31a (rIFN-(3la) in patients with multiple 
sclerosis (MS). The impressive results showed that 6 million 
international units o f rIFN-(3la applied once weekly via the 
intramuscular route was safe and effective in patients with 
relapsing-remitting MS.
For all its merits, we are compelled to point out an error 
in the article [1]. Dr Jacobs’ designation o f  the study mate­
rial as Avon ex is incorrect and misleading. The only IFN- 
3 la used in this study was not as stated in the study, ie, the 
substance with the trade name Avonex, produced by Biogen 
Inc, in Cambridge, Massachusetts, but the Chinese hamster
ovary—aeriveci rIFN -pla developed and produced by Bio- 
feron Biochemische Substanzen Gm bH (Bioferon) in Laup- 
heim, Germany. Today all product rights of the clinically 
tested product are held by Dr Rentschler Biotechnologie 
GmbH (Rentschler), which is continuing the development o f  
its proprietary rIFN-pl a product.
According to a public statement by an FDA official, the 
marketed Biogen product Avonex is only “comparable” with 
[2] but not identical to the Bioferon product used in the trial 
by Dr Jacobs. The FDA obviously decided that the clinical 
data derived from the use o f  Bioferon’s product supports li­
censure o f  Biogen’s product. However, according to our 
knowledge, an identity or comparability between the two 
molecules in terms o f  safety and efficacy in MS has not been 
proved in a pivotal trial.
cured a sufficient supply o f  the interferon-3 to complete our 
study. Biogen also initiated production o f  Avonex at its own 
commercial manufacturing site in Cambridge, Massachusetts. 
Subsequently, Biogen performed extensive tests to demon­
strate the equivalence o f the clinical trial material and the 
material being produced for market use. Based on our clin­
ical study results published in Annals (1996;39:285-294), 
the equivalency tests, and additional clinical studies per­
formed by Biogen with the material being produced for 
commercial use, the FDA granted a license to Biogen to 
manufacture and market Avonex.
Berlex relied on Dr 'Wolf’s arguments and testimony in 
challenging the approval o f  Avonex. The United States Dis­
trict Court dismissed Berlex’s lawsuit on October 7, 1996. 
The Judge in the case made two statements in his ruling that 
are very pertinent. (1) He noted that the FDA had found 
Biogen’s interferon 3  la  manufactured at the Bioferon facility 
to be “biochemically and functionally equivalent” to that 
manufactured at Biogen’s own manufacturing 
Cambridge,
in
H e also that
“FDA’s determination that Avonex is safe, pure and potent is 
amply supported by the record.”
Thus, this issue has already been resolved by both the 
FDA and the United States District Court.
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, N Y '
Central Nervous System W hipple’s Disease
Rentschler Biotechnology, Laupheim, Germany
Wim I. M. Verhagen, M D , PhD, 
Patrick L. M. Huygen, P h D ,t  
and Johanna E. Dalman, MD*
*
Refer
1. Jacobs L, Cook fair D , Rudick R, et al. Intramuscular interferon
(3 la for disease progression in relapsing multiple sclerosis. Ann
Neurol 1996;39:285-294
2, Hearing o f  the Peripheral and Central Nervous System Drugs 
Advisory Committee, Rockville, M D , December 4, 1995.
Reply
Lawrence Jacobs, M D
We read with interest the report by Louis and colleagues (1] 
on guidelines for diagnostic screening and treatment in cen-
. Re-tral nervous system (CNS) Whipple’s disease 
cently, we reported on a similar patient [2]. CNS involve­
ment is reported in about 10 to 43% of the W I) patients 
(for review, see References 1 and 2), but autopsy frequently 
revealed brain involvement, even in the absence of neuro­
logic symptoms [2]. Other cranial nerves than those men­
tioned by Louis and colleagues [11 might be also involved. 
Facial paresis, hearing loss, and vestibulo-oeular reflex im­
pairment have been described 12); the latter two might be 
the result of peripheral labyrinthine or cranial nerve involve-
ment.
Jr W olf’s statements relate primarily to a commercial and 
egal dispute between Biogen, Inc, and Berlex Laboratories, 
the American subsidiary o f  Schering, AG. Schering, one of  
Biogen’s principal competitors, sells interferon 3 lb (Betase- 
ron in the United States) and owns whatever rights Dr 
W olf’s company may have had, to manufacture interferon-3- 
The following brief history serves to clarify the commercial/ 
legal nature of Dr W olf’s concerns.
The Avonex used in our clinical trial was manufactured 
for Biogen on a contract basis at a facility owned by Bio­
feron, a joint venture between Biogen and Dr W olf’s com­
pany, Rentschler. During the course o f  our study, Bioferon 
went into receivership, although Biogen had already pro-
Cerebrospinal fluid protein and leukocyte count are in­
deed often elevated [1, 2|. It is also important that oligo- 
clonal banding and an increased IgG level in the CSF are 
often seen [2], as is a decrease in IgG after treatment [2, 3).
The most effective antibiotic treatment regimen for W D  
is still under discussion. Even clinical and jejunal histological 
improvement after drug treatment do not guarantee an un­
complicated clinical course [2], Fleming and co-workers [4]
WD :1 tetracy-
cline alone had been the initial treatment in 9 o f  the 30
patients who developed CNS relapse. Tetracycline does not 
cross the blood—brain barrier well, unless there is meningeal 
inflammation [5]. Keinath and associates [6] stated that ini-
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cia! treatment do ublodose sulfamethoxa/o le
trimethoprim (ST), given twice daily for 1 year, might be the 
best approach. Because folate deficiency is a potential com­
plication o f such treatment, supplementation is recom­
mended [5]. In many studies, there was no improvement in 
CNS involvement during treatment with tetracycline alone, 
or in combination with other antibiotics [2]. Gaze palsies 
and nystagmus were most responsive to treatment, and de­
mentia was arrested in patients with W D  confined to the 
nervous system (for review, see Reference 2). Remarkable im­
provement in the organic psychosyndrome was noted when 
using ST and slight improvement when using ceftriaxone
[2]. The optimum duration o f antibiotic treatment is un­
known. In the initial stage o f  W D , it appears wise to pre­
scribe ST for a period o f  about 1 year 13). Several of the 
CNS relapse patients had been undergoing treatment for 
about a year or more [2], although Fleming and co-workers
[3] stated that the duration o f  treatment did not have any 
substantial effect on the outcome. We prefer long-term treat­
ment [2]; our patient has now been treated for 32 months 
without having a relapse.
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Treatment Guidelines in Central Nervous System 
Whipple’s Disease
P. J. Schnidcr, Ml),* E. C. Reisinger, MD,
'1'. Berger, MD,* G. J. Krejs, MD,* and E. AulT, MD
published in 1985 [2]. The authors stated that guidelines for 
treatment of cerebral W D have not been proposed so far. 
We recently published treatment guidelines for cerebral W D , 
but our results were published when Louis’ paper was already 
submitted for publication. We reviewed the literature and 
contacted all authors who had reported on cerebral W D
within the past 10 years [3J. The data published by Louis 
support our findings and treatment guidelines.
While antibiotic therapy achieves good results in patients 
with gastrointestinal involvement in W D, the outcome is 
poor with central nervous system (CNS) involvement. On  
the basis of empirical observations, trimethoprim and sulfi 
methoxazole (TMP-SMX) have been recommended for pa­
tients with W D to prevent spread to the CNS involvement 
2|. In our report some o f  the reviewed patients responded
i
well to TMP-SMX, but others did not. Three o f 5 patients 
developed CNS involvement while on TMP-SMX therapy 
3}. Third-generation cephalosporins were successful in pre­
venting CNS involvement in all 4 patients in whom it was 
used [3-5J. Patients initially treated with penicillin and 
streptomycin showed a better long-term outcome than pa­
tients treated with penicillin alone [3]. Louis and colleagues 
reported on 1 patient with cerebral W D  who relapsed after 
initial improvement while on TMP-SMX. When diarrhea 
developed, ceftriaxone (2 g IV daily) for 1 month led to im­
provement. After the patient was switched to doxycycline, a 
second relapse occurred; the patient was again successfully 
treated with ceftriaxone [1]. Another patient improved after 
ceftriaxone (2 g IV daily), and supranuclear gaze palsy and 
lethargy recurred after the patient was switched to TMP- 
SMX therapy [ 1 ]. The outcome in these 2 patients supports 
our findings that TMP-SMX neither prevents nor cures CNS 
involvement in all patients with W D. TMP-SMX reaches 
high intracellular concentrations, hut it is bacteriostatic and 
therefore cannot destroy pathogens in possibly detective mac -
t snorins have beenophages [6|. Third-generation 
shown to be effective in the treatment of cerebral W I) that 
did not respond to TMP-SMX [1, 3). However a low dose 
of ceftriaxone (2 g IV daily) might* be responsible for the 
CNS r el apses after discontinuation of ceftriaxone [1|. Based 
on our own long-term Ibllow-up study and the results of 
Louis and colleagues, we suggest initial treatment of W D  
with intravenous ceftriaxone (instead of penicillin), 2 g twice 
daily, plus streptomycin, I g once daily I or 2 weeks, or a l­
ternatively intravenous TMP-SMX, 960 mg twice daily for I
•>to z  weeks. Follow-up treatment for 1 year should consist of
oral TMP-SMX, 960 mg twice daily, or oral ceflxiine, 400
mg once daily.
*Division of Neurological
Neurology, University o f  Vienna; and Division o f  Infectious
Department o f
Diseases, Department o f
A us trin
* 4'tue, F ra n ze n s lerstty,
We read with interest the review by Louis and colleagues (1 
on the diagnostic guidelines in central nervous system Whip­
ple’s disease (WD). The authors presented guidelines for di­
agnostic screening and selection lor biopsy by reviewing 84 
cases of cerebral W D. For antibiotic treatment the authors 
refer to a review by Keinath and colleagues on antibiotic 
treatment in W D  (including only a few with cerebral WD)
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